BiPar Sciences was a Brisbane, California biopharmaceutical company developing a tumor-selective class of PARP (poly ADP-ribose polymerase) inhibitors for cancer therapy. Its lead candidate, BSI-201 (iniparib), was in mid-stage trials for advanced breast, ovarian, and other tumors. - View it on GitHub